
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Las Vegas - New pharmaceuticals including calcineurin inhibitors represent viable alternatives to traditional treatments for eczematous dermatoses, according to Joseph F. Fowler, Jr., M.D. He is a clinical professor of dermatology in Kentucky's University of Louisville School of Medicine, and estimated he has treated several thousand dermatitis patients.